Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Karanth, Laxminarayan ^a   Barua, Ankur ^b   Kanagasabai, Sachchithanantham ^a   Nair, N S ^c  

^a MELAKA MANIPAL MEDICAL COLLEGE   (India)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^c MANIPAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; FRESH FROZEN PLASMA; TRANEXAMIC ACID; ARGIPRESSIN[1 DEAMINO]; HEMOSTATIC AGENT;

BLEEDING; CESAREAN SECTION; CLINICAL OUTCOME; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HYPERTENSIVE CRISIS; HYPONATREMIA; INFANT MORTALITY; MATERNAL HYPERTENSION; MATERNAL MORTALITY; POSTPARTUM HEMORRHAGE; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEIZURE; SYSTEMATIC REVIEW; BLOOD CLOTTING DISORDER; PREGNANCY COMPLICATION;

BLOOD COAGULATION DISORDERS; DEAMINO ARGININE VASOPRESSIN; FEMALE; HEMOSTATICS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

EID: 84886848210     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009824.pub2     Document Type: Review

References (34)

1. Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, Slack J, Kernoff PB. Inheritance and bleeding in factor XI deficiency. British Journal of Haematology 1988;69(4):521-8.
2. Burrow GN, Wassenaar W, Robertson GL, Sehl H. DDAVP treatment of diabetes insipidus during pregnancy and the post-partum period. Acta Endocrinologica 1981;97(1):23-5.
3. Chediak JR, Alban GM, Maxey B. von Willebrand's disease and pregnancy: management during delivery and outcome of offspring. American Journal of Obstetrics and Gynecology 1986;155(3):618-24.
4. Chi C, Kadir RA. Management of women with inherited disorders in pregnancy. The Obstetrician and Gynecologist 2007;9(1):27-33.
5. Conti M, Mari D, Conti E, Muggiasca ML, Mannucci PM. Pregnancy in women with different types of von Willebrand disease. Obstetrics and Gynecology 1986;68(2):282-5.
6. Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
7. Dreyer NA, Garner S. Registries for robust evidence. JAMA 2009;302(7):790-1.
8. Giangrande PLF. Pregnancy in female with inherited bleeding disorders. Treatment of Haemophila. World Federation of Hemophilia, no 29, 2003:1-5.
9. Greer IA, Lowe GD, Walker JJ, Forbes CD. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. British Journal of Obstetrics and Gynaecology 1991;98(9):909-18.
10. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
11. Higgins JPT, Deeks JJ, Altman DG on behalf of the CSMG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
12. Huq FA, Kadir RA. Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia 2011;17 Suppl 1:20-30.
13. Kadir RA, Economides DL, Braithwaite J, Goldman E, Lee CA. The obstetric experience of carriers of haemophilia. British Journal of Obstetrics and Gynaecology 1997;104(7):803-10.
14. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand's disease or factor XI deficiency. British Journal of Obstetrics and Gynaecology 1998;105(3):314-21.
15. Lee CY, Madrazo B, Drukker BH. Ultrasound evaluation of postpartum uterus in the management of postpartum bleeding. Obstetrics and Gynecology 1981;58(2):227-32.
16. Lee CA, Chi C, Pavord SR, Bolton-Maggs PH, Pollard D, Hinchcliffe-Wood A, et al.The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a task force of UK Haemophilia Centre Doctors' Organization. Haemophilia 2006;12(4):301-6.
17. Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thrombosis and Haemostasis 1987;58(4):1033-6.
18. Levi M, Vink R, de Jonge E. Prevention and treatment of bleeding by pro-hemostatic treatment strategies. Wiener Medizinische Wochenschrift 2003;153(19-20):421-5.
19. Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ 1995;311(7020):1621-5.
20. Lipscomb J, Yabroff R, Brown ML. Health care costing: data, methods, current applications. Medical Care 2009;47(7 Suppl 1):S1-6.
21. Lusher JM, McMillan CW. Severe factor VIII and factor IX deficiency in females. American Journal of Medicine 1978;65(4):637-48.
22. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. British Journal of Haematology 1975;30(1):81-93.
23. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997;90(7):2515-21.
24. Mannncci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII deficient women. Blood 2005;105(8):3382.
25. Committee on Strategies for Small-Number-Participant Clinical Research Trials, Board on Health Sciences Policy (The National Academies Press). Small Clinical Trials: Issues and Challenges (2001). www.nap.edu/catalog/10078.html (accessed 19 September 2012).
26. Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, et al.von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008;14(2):171-232.
27. Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstetrical and Gynecological Survey 1998;53(7):450-5.
28. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
29. Rochelson B, Caruso R, Davenport D, Kaelber A. The use of prophylactic desmopressin (DDAVP) in labor to prevent hemorrhage in a patient with Ehlers-Danlos syndrome. New York State Journal of Medicine 1991;91(6):268-9.
30. Sanchez-Luceros A, Meschengieser SS, Turdo K, Arizo A, Wods AI, Casais P, et al.Evaluation of the clinical safety of desmopressin during pregnancy in women with a low plasmatic von Willebrand factor level and bleeding history. Thrombosis Research 2007;120(3):387-90.
31. Sanofi-Aventis. DDAVP® Nasal Spray (desmopressin acetate) (2007). http://products.sanofi.us/DDAVP_Nasal/DDAVP_Nasal-spray.pdf (accessed 13 March 2012).
32. Stirling Y, Woolf L, North WRS, Senghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thrombosis and Haemostasis 1984;52(2):176-82.
33. Temple RJ. Government viewpoint of clinical trials. Drug Information Journal 1982;16:10-7.
34. Wun T, Paglieroni TG, Lachant NA. Desmopressin stimulates the expression of P-selectin on human platelets in vitro. Journal of Laboratory and Clinical Medicine 1995;126(4):401-9.